Thyroid Eye Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Thyroid Eye Disease remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 197 matched trial records and 72 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600127755 | Methylprednisolone + Teprotumumab-TRBW | Not Applicable; Not yet recruiting | the First Affiliated Hospital of Sun Yat-Sen University | China | Treatment response rate (at the beginning of week 25) | 2030-04-30 |
| NCT07682896 | GenSci098 | Phase 2; Recruiting | Sponsor not listed | United States, Australia | Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) (Baseline, Day 169); Proportion of participants with normal free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) who discontinued anti-thyroid drugs (ATDs), regardless of concomitant levothyroxine use (Baseline, Day 169) | 2027-12-01 |
| ChiCTR2600126205 | Intervention not normalized | Not Applicable; Not yet recruiting | The Ninth People's Hospital of Shanghai Jiaotong University Medical College | China | Reduction in diplopia severity by at least one grade (Three days prior to intravenous pulse corticosteroid therapy 、 after treatment…); An increase of at least 8 degrees in the range of ocular movement in any direction (Three days prior to intravenous pulse corticosteroid therapy 、 after treatment…) | 2028-12-31 |
| NCT07623993 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | United States | Agreement between Glandy CAS and clinician-assessed CAS total score (At each clinic-matched visit (baseline through end-of-treatment, up to 12…); Agreement between Glandy EXO and Hertel exophthalmometry (At each clinic-matched visit (baseline through end-of-treatment, up to 12…) | 2027-06-30 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (Phase 2): the indexed record reports -; -; Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in Either Eye Without Increased Proptosis (≥2 mm Increase) in the Other Eye = 6 Participants.
- IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients (Phase 3): the indexed record reports Proptosis response rate(reduction ≥2 mm, at week 24) = 3.8 %; Proptosis response rate(reduction ≥2 mm, at week 24) = 85.8 %.
- Clinical courses and characteristics of thyroid eye disease patients treated with teprotumumab (Not Applicable): the indexed record reports Clinical activity score(8 infusions) = 2.5 Point.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Methylprednisolone (Approved; GR), Teprotumumab-TRBW (Approved; IGF-1R), GenSci098 (Phase 1; TSHR). Company & Deal Intelligence records identify sponsor context for the First Affiliated Hospital of Sun Yat-Sen University, The Ninth People's Hospital of Shanghai Jiaotong University Medical College. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Thyroid Eye Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
